Tempus AI's stock surged 5.11% in pre-market trading, continuing its volatile upward trend this week. The movement reflects strong investor interest ahead of the market open.

The pre-market surge follows two significant positive developments for the company. Tempus AI recently announced an expanded multi-year partnership with Gilead Sciences, granting the pharmaceutical company enterprise-level access to Tempus AI's AI-driven Lens platform. This will enable broader use of de-identified multimodal datasets across multiple indications to support oncology pipeline development.

Additionally, Tempus Pixel received commercial approval for use in the United States, marking a significant regulatory milestone in the cardiac imaging space. These developments further validate the company's platform value in precision medicine and have been driving momentum throughout the week.